Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.
A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.
A user is seeking a hair loss formula containing Redensyl and Capixyl without caffeine, Saw Palmetto, or other herbs. They want recommendations for such a product.
The user experienced hairline improvement using microneedling once a month with a 12-pin set at 1.5-2.0mm and taking Tru Niagen, alongside a heavily modified diet. They attribute the slow hairline improvement to environmental factors, particularly diet, rather than solely genetic factors.
Hair loss treatment progress with Dut, Min, Keto, needling, and RU/Min/Fin/Dut topical. User noticed improvement, believes RU and needling most effective.
The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.
PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.
Fatty liver and related issues may influence hair loss conditions like Dupa/Aga. Treatments discussed include Minoxidil, finasteride, RU58841, myo-inositol, and L-glutamine.
Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.
The user is using Minoxidil, RU58841, CB-03-01, WAY-316606, Ketoconazole, MK-677, and derma stamping to treat hair loss and has noticed new hair growth, especially around the temples and hairline. They apply different treatments at various times of the day and have seen improvements in skin condition and body hair texture.
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.
The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.
Quitting smoking and vaping, along with taking spirulina, improved hair thickness for some users. Others noted that smoking, vaping, and drinking may contribute to hair thinning.
People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.
A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.
The conversation discusses a hair loss treatment regimen including 5% minoxidil, 2.5mg oral minoxidil, 1mg finasteride, tretinoin cream, derma stamping, derma rolling, scalp massagers, and a mix of vitamins and minerals. The user also considers using maca and adapalene, with advice on potential scalp irritation and the effectiveness of these treatments.
A user shared their positive experience with Laq herbal shampoo and Sevich Batana oil for hair loss due to PCOS and an unbalanced diet. They noticed significant improvement after three weeks of using these products.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
The conversation discusses hair regrowth after a health condition, with the appearance of white substance on the scalp. Suggestions include it being sebum or White Piedra, with a recommendation to try Nizoral.
Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.
The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.
The user is seeking Malassezia-safe treatments for hair loss and currently uses a baby shampoo, a scalp tonic with antifungal ingredients, and aloe gel. They consider using Kirkland Minoxidil 5% drops and possibly consulting a doctor about Finasteride.
PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.
Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.